

# Sang Hoon Ahn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4133489/publications.pdf>

Version: 2024-02-01

469  
papers

17,728  
citations

17405

63  
h-index

25716

108  
g-index

483  
all docs

483  
docs citations

483  
times ranked

14834  
citing authors

#	ARTICLE	IF	CITATIONS
1	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	1.8	2,171
2	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Hepatology International</i> , 2020, 14, 889-919.	1.9	422
3	Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). <i>Hepatology</i> , 2011, 53, 885-894.	3.6	329
4	96-weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , 2018, 68, 672-681.	1.8	291
5	Combination of Tenofovir Disoproxil Fumarate and Peginterferon $\alpha$ -2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 134-144.e10.	0.6	284
6	Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011). <i>Hepatology</i> , 2016, 63, 776-786.	3.6	261
7	Performance of Transient Elastography for the Staging of Liver Fibrosis in Patients with Chronic Hepatitis B: A Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e44930.	1.1	242
8	Genome Replication, Virion Secretion, and e Antigen Expression of Naturally Occurring Hepatitis B Virus Core Promoter Mutants. <i>Journal of Virology</i> , 2003, 77, 6601-6612.	1.5	235
9	Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. <i>Liver International</i> , 2010, 30, 546-553.	1.9	225
10	Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). <i>Hepatology International</i> , 2020, 14, 690-700.	1.9	210
11	A Liver Stiffness Measurement-Based, Noninvasive Prediction Model for High-Risk Esophageal Varices in B-Viral Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2010, 105, 1382-1390.	0.2	194
12	Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2005, 42, 188-194.	1.8	191
13	Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2015, 62, 1304-1310.	1.8	148
14	Prediction of microvascular invasion of hepatocellular carcinoma: Usefulness of peritumoral hypointensity seen on gadoxetate disodium-enhanced hepatobiliary phase images. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 629-634.	1.9	147
15	Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 68, 431-440.	1.8	147
16	HBV Genotypes: Relevance to Natural History, Pathogenesis and Treatment of Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2011, 16, 1169-1186.	0.6	146
17	Controlled attenuation parameter ( $CAP$ ) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. <i>Liver International</i> , 2014, 34, 102-109.	1.9	143
18	Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. <i>Cancer</i> , 2008, 113, 995-1003.	2.0	138

#	ARTICLE	IF	CITATIONS
19	Genome-Wide Association Study Confirming Association of HLA-DP with Protection against Chronic Hepatitis B and Viral Clearance in Japanese and Korean. <i>PLoS ONE</i> , 2012, 7, e39175.	1.1	137
20	A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. <i>Journal of Hepatology</i> , 2019, 71, 456-464.	1.8	131
21	MRP2 haplotypes confer differential susceptibility to toxic liver injury. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 403-415.	0.7	127
22	Usefulness of FibroScan for Detection of Early Compensated Liver Cirrhosis in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1758-1763.	1.1	122
23	Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. <i>Hepatology</i> , 2015, 61, 1851-1859.	3.6	121
24	Association between hepatitis B virus infection and HLA-DR type in Korea. <i>Hepatology</i> , 2000, 31, 1371-1373.	3.6	120
25	Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. <i>Hepatology</i> , 2011, 53, 1486-1493.	3.6	120
26	Prediction of Development of Liver-Related Events by Transient Elastography in Hepatitis B Patients With Complete Virological Response on Antiviral Therapy. <i>American Journal of Gastroenterology</i> , 2014, 109, 1241-1249.	0.2	120
27	MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. <i>Carcinogenesis</i> , 2008, 29, 1192-1196.	1.3	119
28	Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. <i>Liver International</i> , 2008, 28, 393-401.	1.9	113
29	Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study. <i>Yonsei Medical Journal</i> , 2005, 46, 399.	0.9	109
30	Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2010, 51, 415-421.	3.6	107
31	Prediction of microvascular invasion before curative resection of hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2008, 97, 246-252.	0.8	104
32	Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2007, 110, 129-137.	2.0	102
33	Role of <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography in Detecting Extrahepatic Metastasis in Pretreatment Staging of Hepatocellular Carcinoma. <i>Oncology</i> , 2007, 72, 104-110.	0.9	101
34	Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. <i>Gastroenterology</i> , 2019, 157, 227-241.e7.	0.6	99
35	Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. <i>Hepatology</i> , 2015, 62, 1757-1766.	3.6	97
36	Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. <i>Liver International</i> , 2007, 27, 969-976.	1.9	96

#	ARTICLE	IF	CITATIONS
37	How Can We Enhance the Performance of Liver Stiffness Measurement Using FibroScan in Diagnosing Liver Cirrhosis in Patients With Chronic Hepatitis B?. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 66-71.	1.1	94
38	PIVKA-II Is a Useful Tumor Marker for Recurrent Hepatocellular Carcinoma after Surgical Resection. <i>Oncology</i> , 2007, 72, 52-57.	0.9	91
39	Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1120-1127.	1.9	91
40	Liver Stiffness Measurement Using Acoustic Radiation Force Impulse (ARFI) Elastography and Effect of Necroinflammation. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1682-1691.	1.1	90
41	Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 152-166.	3.7	85
42	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 441-453.	3.7	85
43	Autologous Bone Marrow Infusion Activates the Progenitor Cell Compartment in Patients with Advanced Liver Cirrhosis. <i>Cell Transplantation</i> , 2010, 19, 1237-1246.	1.2	84
44	Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). <i>Journal of Hepatology</i> , 2016, 64, 1011-1019.	1.8	84
45	RNA Interference Therapy With ARC520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020, 72, 19-31.	3.6	84
46	Prediction of Liver-Related Events Using Fibroscan in Chronic Hepatitis B Patients Showing Advanced Liver Fibrosis. <i>PLoS ONE</i> , 2012, 7, e36676.	1.1	84
47	Long-term Clinical Outcome of Phase IIb Clinical Trial of Percutaneous Injection with Holmium-166/Chitosan Complex (Milican) for the Treatment of Small Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 543-548.	3.2	82
48	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 776-787.	3.7	82
49	Long-term outcome of chronic hepatitis B based on histological grade and stage. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 383-388.	1.4	79
50	Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. <i>Journal of Gastroenterology</i> , 2016, 51, 830-839.	2.3	78
51	Prediction of postoperative hepatic insufficiency by liver stiffness measurement (FibroScan®) before curative resection of hepatocellular carcinoma: a pilot study. <i>Hepatology International</i> , 2008, 2, 471-7.	1.9	77
52	What are "true normal" liver stiffness values using FibroScan®?: a prospective study in healthy living liver and kidney donors in South Korea. <i>Liver International</i> , 2010, 30, 268-274.	1.9	76
53	Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial embolization prognostic score. <i>Liver International</i> , 2016, 36, 100-107.	1.9	76
54	Evaluation of Methods for Monitoring Drug Resistance in Chronic Hepatitis B Patients during Lamivudine Therapy Based on Mass Spectrometry and Reverse Hybridization. <i>Antiviral Therapy</i> , 2005, 10, 441-449.	0.6	73

#	ARTICLE	IF	CITATIONS
55	Sequence variation upstream of precore translation initiation codon reduces hepatitis B virus e antigen production. <i>Gastroenterology</i> , 2003, 125, 1370-1378.	0.6	71
56	Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. <i>European Journal of Cancer</i> , 2013, 49, 826-834.	1.3	71
57	Prediction of Recurrence after Curative Resection of Hepatocellular Carcinoma using Liver Stiffness Measurement (FibroScan®). <i>Annals of Surgical Oncology</i> , 2012, 19, 4278-4286.	0.7	70
58	Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 279.	4.5	70
59	Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 344-353.	0.6	68
60	Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. <i>American Journal of Gastroenterology</i> , 2020, 115, 584-595.	0.2	68
61	Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1377-1384.	1.2	67
62	Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. <i>Gut</i> , 2014, 63, 996-1004.	6.1	67
63	High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms. <i>Advances in Therapy</i> , 2015, 32, 637-649.	1.3	67
64	Liver Stiffness Measurement in Combination With Noninvasive Markers for the Improved Diagnosis of B-viral Liver Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 267-271.	1.1	66
65	Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 235-241.	0.6	64
66	Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. <i>Liver International</i> , 2016, 36, 92-99.	1.9	64
67	Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e41964.	1.1	64
68	Prognostic value of $\alpha$ -fetoprotein and des- $\gamma$ -carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. <i>BMC Cancer</i> , 2013, 13, 5.	1.1	60
69	Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 2568-2575.	1.3	59
70	Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. <i>Vaccine</i> , 2012, 30, 2689-2696.	1.7	58
71	Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 659-667.	1.2	57
72	Prognostic significance of the worst grade in hepatocellular carcinoma with heterogeneous histologic grades of differentiation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1384-1390.	1.4	57

#	ARTICLE	IF	CITATIONS
73	Prognostic value of 18Fâ€FDC PET for hepatocellular carcinoma patients treated with sorafenib. <i>Liver International</i> , 2011, 31, 1144-1149.	1.9	56
74	Risk Assessment of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis by a Liver Stiffness Measurement-Based Model. <i>American Journal of Gastroenterology</i> , 2011, 106, 1654-1662.	0.2	56
75	Early ð±-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 369-376.	1.9	55
76	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. <i>Journal of Hepatology</i> , 2022, 76, 1042-1050.	1.8	54
77	Normal liver elasticity values using acoustic radiation force impulse imaging: A prospective study in healthy living liver and kidney donors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 130-136.	1.4	53
78	Surgical Resection After Down-Staging of Locally Advanced Hepatocellular Carcinoma by Localized Concurrent Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 3646-3653.	0.7	53
79	Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2016, 22, 8314.	1.4	52
80	Liver stiffness measurement using FibroScan <sup>®</sup> is influenced by serum total bilirubin in acute hepatitis. <i>Liver International</i> , 2009, 29, 810-815.	1.9	51
81	Characterization of focal liver masses using acoustic radiation force impulse elastography. <i>World Journal of Gastroenterology</i> , 2013, 19, 219.	1.4	51
82	Clinical Features and Prognosis of Spontaneous Bacterial Peritonitis in Korean Patients with Liver Cirrhosis: A Multicenter Retrospective Study. <i>Gut and Liver</i> , 2009, 3, 197-204.	1.4	51
83	Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2009, 81, 1002-1008.	2.5	50
84	How to Predict HCC Development in Patients with Chronic B Viral Liver Disease?. <i>Intervirology</i> , 2005, 48, 23-28.	1.2	49
85	The Accuracy of Noninvasive Methods in Predicting the Development of Hepatocellular Carcinoma and Hepatic Decompensation in Patients With Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 518-525.	1.1	49
86	Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke. <i>Atherosclerosis</i> , 2017, 260, 156-162.	0.4	49
87	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e784-e793.	2.4	49
88	Clinical outcome of renal transplantation in patients with positive preâ€transplant hepatitis B surface antigen. <i>Journal of Medical Virology</i> , 2007, 79, 1655-1663.	2.5	48
89	Factors associated with significant liver fibrosis assessed using transient elastography in general population. <i>World Journal of Gastroenterology</i> , 2015, 21, 1158.	1.4	48
90	Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. <i>Hepatology International</i> , 2010, 4, 386-395.	1.9	47

#	ARTICLE	IF	CITATIONS
91	<sup>18</sup> Fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. <i>Cancer</i> , 2011, 117, 4779-4787.	2.0	47
92	Hepatitis B Virus Cure: Targets and Future Therapies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 213.	1.8	47
93	Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. <i>Journal of Medical Virology</i> , 2010, 82, 1835-1842.	2.5	46
94	Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: Results from a multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 526-532.	1.8	46
95	A Comparative Analysis of Hepatocellular Carcinoma after Hepatic Resection in Young versus Elderly Patients. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1736-1743.	0.9	45
96	Prospective Validation of FibroTest in Comparison with Liver Stiffness for Predicting Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e35825.	1.1	45
97	Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3487-3497.	1.1	45
98	Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1850-1859.e4.	2.4	45
99	Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 1008-1017.	1.9	44
100	Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells. <i>Journal of Hepatology</i> , 2019, 71, 289-300.	1.8	44
101	Predictive factors for long-term survival in patients with clinically significant portal hypertension following resection of hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 485-493.	1.9	43
102	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 196-204.	1.9	43
103	Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. <i>Hepatology International</i> , 2010, 4, 673-680.	1.9	42
104	Gastrointestinal Complications After Concurrent Chemoradiation Therapy in Patients With Hepatocellular Carcinoma: Endoscopic Findings and Risk Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1343-1351.	0.4	42
105	Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. <i>Oncology</i> , 2011, 81, 41-49.	0.9	42
106	Survival of Hepatocellular Carcinoma Patients May be Improved in Surveillance Interval not More Than 6 Months Compared With More Than 6 Months. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 538-544.	1.1	42
107	Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 286-294.	1.1	42
108	Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 882-891.	0.2	42

#	ARTICLE	IF	CITATIONS
109	Hepatocellular carcinoma in Budd-Chiari syndrome: A single center experience with long-term follow-up in South Korea. <i>World Journal of Gastroenterology</i> , 2012, 18, 1946.	1.4	42
110	No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. <i>BMC Medical Genetics</i> , 2012, 13, 47.	2.1	40
111	New Susceptibility and Resistance HLA-DP Alleles to HBV-Related Diseases Identified by a Trans-Ethnic Association Study in Asia. <i>PLoS ONE</i> , 2014, 9, e86449.	1.1	40
112	Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B. <i>Antiviral Therapy</i> , 2011, 16, 77-87.	0.6	38
113	Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization. <i>Clinical Cancer Research</i> , 2013, 19, 1503-1511.	3.2	38
114	Quantification of HBsAg: Basic virology for clinical practice. <i>World Journal of Gastroenterology</i> , 2011, 17, 283.	1.4	38
115	Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea. <i>Journal of Medical Virology</i> , 2006, 78, 1564-1571.	2.5	37
116	Ascitic fluid infection in patients with hepatitis B virus-related liver cirrhosis: Culture-negative neutrocytic ascites versus spontaneous bacterial peritonitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 122-128.	1.4	37
117	Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. <i>Hepatology</i> , 2014, 60, 1911-1919.	3.6	37
118	Validation of PAGE model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Liver International</i> , 2017, 37, 1788-1795.	1.9	37
119	<i>Wisteria floribunda</i> agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development. <i>Liver International</i> , 2017, 37, 879-887.	1.9	37
120	Gamma-glutamyl transpeptidase-to-platelet ratio is an independent predictor of hepatitis B virus-related liver cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1221-1229.	1.4	37
121	Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Cancers</i> , 2019, 11, 509.	1.7	37
122	Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 290-299.	1.4	37
123	Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1722-1727.	1.4	36
124	Impact of Spontaneous Hepatocellular Carcinoma Rupture on Recurrence Pattern and Long-term Surgical Outcomes after Partial Hepatectomy. <i>World Journal of Surgery</i> , 2014, 38, 2070-2078.	0.8	36
125	Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 487-496.	1.4	36
126	Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. <i>Journal of Medical Virology</i> , 2003, 71, 367-375.	2.5	35



#	ARTICLE	IF	CITATIONS
127	Usefulness of urine strip test in the rapid diagnosis of spontaneous bacterial peritonitis. <i>Liver International</i> , 2005, 25, 1197-1201.	1.9	35
128	Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 849-856.	0.8	35
129	Combined measurement of preoperative Î±-fetoprotein and des-Î³-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis B-related hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2012, 131, 2332-2341.	2.3	35
130	Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. <i>Liver International</i> , 2015, 35, 1054-1062.	1.9	34
131	Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2015, 60, 573-581.	1.1	34
132	Emerging Therapies for Hepatitis C. <i>Gut and Liver</i> , 2014, 8, 471-479.	1.4	34
133	Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a population-based nationwide study. <i>Liver International</i> , 2008, 28, 1389-1395.	1.9	33
134	Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 165-173.	1.1	33
135	Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2015, 56, 1296.	0.9	33
136	Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. <i>Journal of Infectious Diseases</i> , 2017, 216, 1407-1414.	1.9	33
137	Factors Affecting the Accuracy of Controlled Attenuation Parameter (CAP) in Assessing Hepatic Steatosis in Patients with Chronic Liver Disease. <i>PLoS ONE</i> , 2014, 9, e98689.	1.1	33
138	Changes in Serum and Ascitic Monocyte Chemotactic Protein-1 (MCP-1) and IL-10 Levels in Cirrhotic Patients with Spontaneous Bacterial Peritonitis. <i>Journal of Interferon and Cytokine Research</i> , 2007, 27, 227-230.	0.5	32
139	Efficacy and Safety of Transarterial Chemoembolization in Recurrent Hepatocellular Carcinoma After Curative Surgical Resection. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 564-569.	0.6	32
140	Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers. <i>Liver International</i> , 2012, 32, 796-802.	1.9	32
141	Investigation of Oncogenic Cooperation in Simple Liver-Specific Transgenic Mouse Models Using Noninvasive In Vivo Imaging. <i>PLoS ONE</i> , 2013, 8, e98689.	1.1	32
142	Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. <i>Liver International</i> , 2014, 34, 1216-1223.	1.9	32
143	A Novel Model to Predict Esophageal Varices in Patients with Compensated Cirrhosis Using Acoustic Radiation Force Impulse Elastography. <i>PLoS ONE</i> , 2015, 10, e0121009.	1.1	32
144	Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1647-1656.e6.	2.4	32

#	ARTICLE	IF	CITATIONS
145	Liver Fibrosis, Not Steatosis, Associates with Long-Term Outcomes in Ischaemic Stroke Patients. <i>Cerebrovascular Diseases</i> , 2019, 47, 32-39.	0.8	32
146	Molecular and clinical characteristics of hepatitis B virus in Korea. <i>Journal of Medical Virology</i> , 2010, 82, 1126-1134.	2.5	31
147	A novel liver stiffness measurement-based prediction model for cirrhosis in hepatitis B patients. <i>Liver International</i> , 2010, 30, 1073-1081.	1.9	31
148	Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in <sc>Korea: A nationwide, multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 128-134.	1.4	31
149	The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter. <i>Yonsei Medical Journal</i> , 2016, 57, 885.	0.9	31
150	Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 283-293.	4.5	31
151	A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 24-32.	4.5	31
152	The Clinical Impact of Early Detection of the Ymdd Mutant on the Outcomes of Long-Term Lamivudine Therapy in Patients with Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 447-455.	0.6	31
153	Predictive Value of Liver Cell Dysplasia for Development of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 738-743.	1.1	30
154	Transient elastography in chronic hepatitis B: An Asian perspective. <i>World Journal of Gastroenterology</i> , 2010, 16, 5173.	1.4	30
155	Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 313-322.	1.4	30
156	Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 722-729.	0.4	30
157	Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 832-837.	1.1	30
158	Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1037-1042.	0.4	29
159	Ascites and spontaneous bacterial peritonitis: An Asian perspective. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1494-1503.	1.4	29
160	Normal liver stiffness values differ between men and women: A prospective study for healthy living liver and kidney donors in a native Korean population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 781-788.	1.4	29
161	Clinical usefulness of double biomarkers <sc>AFP</sc> and <sc>PIVKA-II</sc> for subdividing prognostic groups in locally advanced hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 313-321.	1.9	29
162	Red cell volume distribution width to platelet ratio in assessment of liver fibrosis in patients with chronic hepatitis B. <i>Liver International</i> , 2016, 36, 24-30.	1.9	29

#	ARTICLE	IF	CITATIONS
163	External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2019, 39, 1624-1630.	1.9	29
164	Radiation-induced hepatic toxicity after radiotherapy combined with chemotherapy for hepatocellular carcinoma. <i>Hepatology Research</i> , 2007, 37, 906-913.	1.8	28
165	Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2013, 33, 180-189.	1.9	28
166	Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1536-1542.	1.4	28
167	Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus. <i>Medicine (United States)</i> , 2016, 95, e3328.	0.4	28
168	Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1168-1178.	2.9	28
169	Clinicopathological Characteristics in Combined Hepatocellular-Cholangiocarcinoma: A Single Center Study in Korea. <i>Yonsei Medical Journal</i> , 2011, 52, 753.	0.9	27
170	Inhibition of tumour angiogenesis and growth by small hairpin <i>hif-1</i> and <i>il-8</i> in hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 632-642.	1.9	27
171	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 46-60.e8.	2.4	27
172	Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 97-107.	1.9	27
173	Association between IL28B Polymorphisms and Spontaneous Clearance of Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2013, 8, e69166.	1.1	26
174	Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1463-1469.	1.4	26
175	Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 475-482.	1.7	26
176	Efficacy of Lenervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3043-3045.e1.	2.4	26
177	The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. <i>European Journal of Internal Medicine</i> , 2021, 89, 48-55.	1.0	26
178	Rescue Monotherapy in Lamivudine-Resistant Hepatitis B e Antigen-Positive Chronic Hepatitis B: Adefovir versus Entecavir. <i>Antiviral Therapy</i> , 2009, 14, 705-712.	0.6	26
179	MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4919-4928.	1.1	26
180	Use of the Delta Neutrophil Index as a Prognostic Factor of Mortality in Patients with Spontaneous Bacterial Peritonitis: Implications of a Simple and Useful Marker. <i>PLoS ONE</i> , 2014, 9, e86884.	1.1	25

#	ARTICLE	IF	CITATIONS
181	Relationship between Cerebral Microbleeds and Liver Stiffness Determined by Transient Elastography. PLoS ONE, 2015, 10, e0139227.	1.1	25
182	Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. Cancer Medicine, 2019, 8, 5023-5032.	1.3	25
183	Clinical Features and Treatment Outcomes of Upper Gastrointestinal Bleeding in Patients with Cirrhosis. Journal of Korean Medical Science, 2008, 23, 635.	1.1	24
184	Liver Stiffness Value-Based Risk Estimation of Late Recurrence after Curative Resection of Hepatocellular Carcinoma: Development and Validation of a Predictive Model. PLoS ONE, 2014, 9, e99167.	1.1	24
185	Risk Assessment of Liver-related Events Using Transient Elastography in Patients With Chronic Hepatitis B Receiving Entecavir. Journal of Clinical Gastroenterology, 2014, 48, 272-278.	1.1	24
186	Early $\alpha$ -fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Journal of Hepatocellular Carcinoma, 2015, 2, 39.	1.8	24
187	Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis. Gut and Liver, 2017, 11, 828-834.	1.4	24
188	Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 503-510.	1.4	24
189	Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. Clinical Gastroenterology and Hepatology, 2020, 18, 693-699.e1.	2.4	24
190	Hepatitis C Virus and Antiviral Drug Resistance. Gut and Liver, 2016, 10, 890-895.	1.4	24
191	Preoperative Radiologic and Postoperative Pathologic Risk Factors for Early Intra-Hepatic Recurrence in Hepatocellular Carcinoma Patients Who Underwent Curative Resection. Yonsei Medical Journal, 2009, 50, 789.	0.9	23
192	Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis. Hepatology International, 2017, 11, 268-276.	1.9	23
193	Urgency to treat patients with chronic hepatitis C in Asia. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 966-974.	1.4	23
194	An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. Liver International, 2020, 40, 1736-1743.	1.9	23
195	Long-term clinical outcome of large volume paracentesis with intravenous albumin in patients with spontaneous bacterial peritonitis: A randomized prospective study. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1215-1222.	1.4	22
196	Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study. Hepatology International, 2012, 6, 763-769.	1.9	22
197	Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. OncoTargets and Therapy, 2013, 6, 1463.	1.0	22
198	Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma. OncoTargets and Therapy, 2015, 8, 347.	1.0	22

#	ARTICLE	IF	CITATIONS
199	Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. <i>Liver International</i> , 2015, 35, 1722-1730.	1.9	22
200	Tumor Necrosis Factor-producing T-regulatory Cells Are Associated With Severe Liver Injury in Patients With Acute Hepatitis A. <i>Gastroenterology</i> , 2018, 154, 1047-1060.	0.6	22
201	Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Liver International</i> , 2018, 38, 676-686.	1.9	22
202	Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1317-1325.	1.4	22
203	Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy. <i>Gut and Liver</i> , 2021, 15, 117-127.	1.4	22
204	YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation. <i>Hepatology</i> , 2021, 74, 2605-2621.	3.6	22
205	Dickkopf-1 induces angiogenesis via VEGF receptor 2 regulation independent of the Wnt signaling pathway. <i>Oncotarget</i> , 2017, 8, 58974-58984.	0.8	22
206	Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 842-847.	1.4	21
207	Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. <i>Cancers</i> , 2020, 12, 2527.	1.7	21
208	Partial virological response to entecavir in treatment-naïve patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2011, 16, 469-477.	0.6	20
209	Adjuvant Hepatic Arterial Infusional Chemotherapy with 5-Fluorouracil and Cisplatin after Curative Resection of Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 184-191.	0.9	20
210	Risk Assessment of Development of Hepatic Decompensation in Histologically Proven Hepatitis B Viral Cirrhosis Using Liver Stiffness Measurement. <i>Digestion</i> , 2012, 85, 219-227.	1.2	20
211	Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e77240.	1.1	20
212	Lesson from 610 liver resections of hepatocellular carcinoma in a single center over 10 years. <i>World Journal of Surgical Oncology</i> , 2014, 12, 192.	0.8	20
213	Reimbursement policies in the Asia-Pacific for chronic hepatitis B. <i>Hepatology International</i> , 2015, 9, 43-51.	1.9	20
214	Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. <i>Liver International</i> , 2016, 36, 1108-1115.	1.9	20
215	Effect of S267F variant of NTCP on the patients with chronic hepatitis B. <i>Scientific Reports</i> , 2017, 7, 17634.	1.6	20
216	Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. <i>Scientific Reports</i> , 2019, 9, 2508.	1.6	20

#	ARTICLE	IF	CITATIONS
217	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222.	6.1	20
218	Serum <i>Wisteria floribunda</i> agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 33-44.	4.5	20
219	Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 390-399.	4.5	20
220	The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. <i>Gut and Liver</i> , 2020, 14, 765-774.	1.4	20
221	Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 729-735.	1.4	19
222	Hepatitis B e antigen-negative mutations in the precore and core promoter regions in Korean patients. <i>Journal of Medical Virology</i> , 2009, 81, 594-601.	2.5	19
223	Variability in liver stiffness values from different intercostal spaces. <i>Liver International</i> , 2009, 29, 760-766.	1.9	19
224	Role of splenectomy in patients with hepatocellular carcinoma and hypersplenism. <i>ANZ Journal of Surgery</i> , 2013, 83, 865-870.	0.3	19
225	Abnormal Liver Stiffness Assessed Using Transient Elastography (Fibroscan®) in HIV-Infected Patients without HBV/HCV Coinfection Receiving Combined Antiretroviral Treatment. <i>PLoS ONE</i> , 2013, 8, e52720.	1.1	19
226	Knockdown of HIF-1 $\alpha$ and IL-8 induced apoptosis of hepatocellular carcinoma triggers apoptosis of vascular endothelial cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2016, 21, 85-95.	2.2	19
227	Staged partial hepatectomy versus transarterial chemoembolization for the treatment of spontaneous hepatocellular carcinoma rupture: a multicenter analysis in Korea. <i>Annals of Surgical Treatment and Research</i> , 2019, 96, 275.	0.4	19
228	Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 106-115.	0.4	19
229	Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 295-304.	4.5	19
230	Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. <i>Gut and Liver</i> , 2020, 14, 626-635.	1.4	19
231	Correlation between quantitative serum HBsAg and HBV DNA test in Korean patients who showed high level of HBsAg. <i>Journal of Clinical Pathology</i> , 2010, 63, 1027-1031.	1.0	18
232	Controversies in Surveillance and Early Diagnosis of Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 56-60.	0.9	18
233	Probability-Based Interpretation of Liver Stiffness Measurement in Untreated Chronic Hepatitis B Patients. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1448-1456.	1.1	18
234	Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B. <i>Liver International</i> , 2015, 35, 455-462.	1.9	18

#	ARTICLE	IF	CITATIONS
235	Predictive Factors of Spontaneous Bacterial Peritonitis Caused by Gram-Positive Bacteria in Patients With Cirrhosis. <i>Medicine (United States)</i> , 2016, 95, e3489.	0.4	18
236	Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2150-2158.	1.1	18
237	Using transient elastography to predict hepatocellular carcinoma recurrence after radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1079-1086.	1.4	18
238	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1950-1958.e7.	2.4	18
239	Advanced Liver Fibrosis Predicts Unfavorable Long-Term Prognosis in First-Ever Ischemic Stroke or Transient Ischemic Attack. <i>Cerebrovascular Diseases</i> , 2020, 49, 474-480.	0.8	18
240	Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. <i>Hepatology International</i> , 2021, 15, 1083-1092.	1.9	18
241	Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance. <i>PLoS ONE</i> , 2015, 10, e0136728.	1.1	18
242	Early Predictor of Mortality due to Irreversible Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2013, 37, 1028-1033.	0.8	17
243	A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. <i>Hepatology International</i> , 2016, 10, 947-955.	1.9	17
244	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018, 38, 1179-1187.	1.9	17
245	Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2808-2810.e2.	2.4	17
246	Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00036.	1.3	17
247	Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: A retrospective monocentric study. <i>Modern Rheumatology</i> , 2020, 30, 70-77.	0.9	17
248	Dynamics of the Liver Stiffness Value Using Transient Elastography during the Perioperative Period in Patients with Valvular Heart Disease. <i>PLoS ONE</i> , 2014, 9, e92795.	1.1	17
249	Factors Influencing the Diagnostic Accuracy of Acoustic Radiation Force Impulse Elastography in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2016, 10, 275.	1.4	17
250	Anti-hepatitis A virus seroprevalence among patients with chronic viral liver disease in Korea. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 923-926.	0.8	16
251	Prospective validation of P2/MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis. <i>Liver International</i> , 2010, 30, 860-866.	1.9	16
252	How Many Valid Measurements Are Necessary to Assess Liver Fibrosis Using FibroScan® in Patients with Chronic Viral Hepatitis? An Analysis of Subjects with at Least 10 Valid Measurements. <i>Yonsei Medical Journal</i> , 2012, 53, 337.	0.9	16

#	ARTICLE	IF	CITATIONS
253	Antibody-Secreting Cells with a Phenotype of Ki-67 <sup>low</sup> , CD138 <sup>high</sup> , CD31 <sup>high</sup> , and CD38 <sup>high</sup> Secrete Nonspecific IgM during Primary Hepatitis A Virus Infection. <i>Journal of Immunology</i> , 2013, 191, 127-134.	0.4	16
254	Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1005-1011.	1.4	16
255	Prevention of Hepatocellular Carcinoma: Beyond Hepatitis B Vaccination. <i>Seminars in Oncology</i> , 2015, 42, 316-328.	0.8	16
256	Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background. <i>BMC Gastroenterology</i> , 2016, 16, 13.	0.8	16
257	Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. <i>Liver International</i> , 2018, 38, 1655-1663.	1.9	16
258	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1429-1437.	1.0	16
259	Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1217-1225.	0.2	16
260	Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response. <i>Gut and Liver</i> , 2016, 10, 429-36.	1.4	16
261	Treatment Outcome of Transcatheter Arterial Chemoinfusion According to Anticancer Agents and Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma (TNM Stage IVa). <i>Yonsei Medical Journal</i> , 2004, 45, 847.	0.9	15
262	Clarification Required for the Definition of Hepatitis B Virus Subgenotypes C1 and C2. <i>Intervirology</i> , 2009, 52, 321-322.	1.2	15
263	Can preoperative diffusion-weighted MRI predict postoperative hepatic insufficiency after curative resection of HBV-related hepatocellular carcinoma? A pilot study. <i>Magnetic Resonance Imaging</i> , 2010, 28, 802-811.	1.0	15
264	Clinical Efficacy of a 24-months Course of Lamivudine Therapy in Patients with HBeAg Negative Chronic Hepatitis B: A Long-term Prospective Study. <i>Journal of Korean Medical Science</i> , 2010, 25, 882.	1.1	15
265	Optimal Time for Restoring the Reliability of Liver Stiffness Measurement in Patients With Chronic Hepatitis B Experiencing Acute Exacerbation. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 602-607.	1.1	15
266	Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 396-406.	0.4	15
267	Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1998-2005.	1.4	15
268	Sequence analysis and functional characterization of full-length hepatitis B virus genomes from Korean cirrhotic patients with or without liver cancer. <i>Virus Research</i> , 2017, 235, 86-95.	1.1	15
269	Long-Term Follow-Up of Patients after Autologous Bone Marrow Cell Infusion for Decompensated Liver Cirrhosis. <i>Cell Transplantation</i> , 2017, 26, 1059-1066.	1.2	15
270	Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1194-1200.e1.	0.2	15



#	ARTICLE	IF	CITATIONS
271	Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>Hepatology International</i> , 2021, 15, 892-900.	1.9	15
272	Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1570-1578.	1.0	15
273	Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study. <i>Diabetes and Metabolism</i> , 2022, 48, 101344.	1.4	15
274	Normal enhanced liver fibrosis (<sc>ELF</sc>) values in apparently healthy subjects undergoing a health checkup and in living liver donors in South Korea. <i>Liver International</i> , 2013, 33, 706-713.	1.9	14
275	Normal Controlled Attenuation Parameter Values: A Prospective Study of Healthy Subjects Undergoing Health Checkups and Liver Donors in Korea. <i>Digestive Diseases and Sciences</i> , 2015, 60, 234-242.	1.1	14
276	Transient Elastography is Superior to FIB-4 in Assessing the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Medicine (United States)</i> , 2016, 95, e3434.	0.4	14
277	Incidence and risk factors of delayed postpolypectomy bleeding in patients with chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 618-624.	0.6	14
278	Paper Alert. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1295-1298.	0.8	14
279	IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses. <i>Journal of Hepatology</i> , 2020, 73, 72-83.	1.8	14
280	Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 786-797.	1.4	14
281	Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 519-528.	1.9	14
282	Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 847-853.	1.4	13
283	Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1528-1534.	1.4	13
284	Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1283-1290.	0.6	13
285	An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. <i>Journal of Viral Hepatitis</i> , 2020, 27, 316-322.	1.0	13
286	Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00140.	1.3	13
287	Artificial intelligence in liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 539-542.	1.4	13
288	Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 956-958.e2.	2.4	13

#	ARTICLE	IF	CITATIONS
289	Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 29.	4.5	13
290	Non-invasive prediction of forthcoming cirrhosis-related complications. <i>World Journal of Gastroenterology</i> , 2014, 20, 2613.	1.4	13
291	Non-invasive assessment of liver fibrosis: Time to move from cross-sectional studies to longitudinal ones. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1472-1473.	1.4	12
292	A 96-Week Randomized Trial of Switching to Entecavir in Chronic Hepatitis B Patients with a Partial Virological Response to Lamivudine. <i>Antiviral Therapy</i> , 2012, 17, 1563-1570.	0.6	12
293	Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1348-1355.e2.	2.4	12
294	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. <i>European Journal of Internal Medicine</i> , 2021, 84, 68-73.	1.0	12
295	Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e794-e807.	2.4	12
296	Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1703-1713.	1.4	12
297	Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2013, 7, 329-334.	1.4	12
298	Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. <i>Gut and Liver</i> , 2019, 13, 197-205.	1.4	12
299	Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 1328-1336.	1.9	12
300	Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. <i>Diabetologia</i> , 2022, 65, 518-527.	2.9	12
301	Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study. <i>American Journal of Gastroenterology</i> , 2022, 117, 758-768.	0.2	12
302	What is the role of diagnostic laparoscopy in a gastroenterology unit?. <i>Journal of Gastroenterology</i> , 2007, 42, 881-886.	2.3	11
303	Combination of preS Deletions and A1762T/G1764A Mutations in HBV Subgenotype C2 Increases the Risk of Developing HCC. <i>Intervirology</i> , 2012, 55, 112-118.	1.2	11
304	Acute Variceal Hemorrhage in Patients with Liver Cirrhosis: Weekend versus Weekday Admissions. <i>Yonsei Medical Journal</i> , 2012, 53, 318.	0.9	11
305	Spontaneous Bacterial Peritonitis in Patients with Hepatitis B Virus-Related Liver Cirrhosis: Community-Acquired versus Nosocomial. <i>Yonsei Medical Journal</i> , 2012, 53, 328.	0.9	11
306	Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2013, 6, 755.	1.0	11

#	ARTICLE	IF	CITATIONS
307	Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 58-65.	0.8	11
308	Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2021, 15, 420-429.	1.4	11
309	Discordance between Liver Biopsy and FibroTest in Assessing Liver Fibrosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2013, 8, e55759.	1.1	11
310	Silencing of Hypoxia-Inducible Factor-1 $\beta$ Induces Anti-Tumor Effects in Hepatoma Cell Lines under Tumor Hypoxia. <i>PLoS ONE</i> , 2014, 9, e103304.	1.1	11
311	Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 82.	4.5	11
312	A Case of Embryonal Sarcoma of the Liver Mimicking a Hydatid Cyst in an Adult. <i>Gut and Liver</i> , 2010, 4, 245-249.	1.4	11
313	Normal range of alanine aminotransferase levels for Asian population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 219-220.	1.4	10
314	Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. <i>Investigational New Drugs</i> , 2012, 30, 1150-1157.	1.2	10
315	Maintaining remission in lamivudine-resistant patients with a virological response to adefovir after lamivudine therapy. <i>Liver International</i> , 2014, 34, 1543-1549.	1.9	10
316	Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 346-359.	4.5	10
317	Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 261.	4.5	10
318	Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study). <i>Clinical and Molecular Hepatology</i> , 2016, 22, 443-449.	4.5	10
319	A quantile regression approach to explain the relationship of Fatigue and Cortisol, Cytokine among Koreans with Hepatitis B. <i>Scientific Reports</i> , 2018, 8, 16434.	1.6	9
320	Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2811-2813.e1.	2.4	9
321	Predictors of Discordance in the Assessment of Skeletal Muscle Mass between Computed Tomography and Bioimpedance Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 322.	1.0	9
322	Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals. <i>Cancers</i> , 2020, 12, 3414.	1.7	9
323	Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107747.	1.2	9
324	Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00290.	1.3	9

#	ARTICLE	IF	CITATIONS
325	Spontaneous HBsAg loss in Korean patients: relevance of viral genotypes, S gene mutations, and covalently closed circular DNA copy numbers. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 251.	4.5	9
326	Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 147-153.	4.5	9
327	Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2015, 9, 776.	1.4	9
328	Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B. <i>Liver International</i> , 2022, 42, 1017-1026.	1.9	9
329	Clinical Course of Virologic Breakthrough after Emergence of YMDD Mutations in HBeAg-Positive Chronic Hepatitis B. <i>Intervirology</i> , 2008, 51, 293-298.	1.2	8
330	Clinical features and prognosis of hepatocellular carcinoma with respect to pre- $\epsilon$ deletion and basal core promoter mutations of hepatitis B virus Genotype C2. <i>Journal of Medical Virology</i> , 2011, 83, 2088-2095.	2.5	8
331	Lamivudine plus adefovir vs. entecavir in HBsAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. <i>Liver International</i> , 2012, 32, 1179-1185.	1.9	8
332	A Novel Estimation of the Relative Economic Value in Terms of Different Chronic Hepatitis B Treatment Options. <i>PLoS ONE</i> , 2013, 8, e57900.	1.1	8
333	Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B. <i>Journal of Medical Virology</i> , 2016, 88, 1027-1034.	2.5	8
334	An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys). <i>Medicine (United States)</i> , 2014, 93, 1047-1054.	0.4	8
335	Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. <i>Hepatology International</i> , 2017, 11, 292-299.	1.9	8
336	Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3660-3668.	1.1	8
337	Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 363.	1.1	8
338	Follow-Up Liver Stiffness Measurements after Liver Resection Influence Oncologic Outcomes of Hepatitis-B-Associated Hepatocellular Carcinoma with Liver Cirrhosis. <i>Cancers</i> , 2019, 11, 425.	1.7	8
339	Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2021, 28, 95-104.	1.0	8
340	Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00299.	1.3	8
341	No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1545-1553.	1.0	8
342	Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 4567.	1.7	8

#	ARTICLE	IF	CITATIONS
343	Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA &lt;math>\geq 2,000</math> IU/mL. <i>American Journal of Gastroenterology</i> , 2022, 117, 288-294.	0.2	8
344	Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2018, 12, 190-200.	1.4	8
345	Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety. <i>Gut and Liver</i> , 2018, 12, 324-330.	1.4	8
346	Prediction of Significant Fibrosis in Chronic Hepatitis C Patients with Normal ALT. <i>Hepato-Gastroenterology</i> , 2011, 58, 1321-1327.	0.5	8
347	Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria. <i>Frontiers in Medicine</i> , 2022, 9, 869190.	1.2	8
348	Association Between Polymorphism of Tumor Necrosis Factor- $\beta$ Promoter and Response to Lamivudine Treatment in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2043-2048.	1.1	7
349	External Validation of P2/MS and Comparison with Other Simple Non-invasive Indices for Predicting Liver Fibrosis in HBV-Infected Patients. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2636-2643.	1.1	7
350	Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. <i>Hepatology International</i> , 2012, 6, 696-706.	1.9	7
351	Casein Kinase II Inhibitor Enhances Production of Infectious Genotype 1a Hepatitis C Virus (H77S). <i>PLoS ONE</i> , 2014, 9, e113938.	1.1	7
352	Pre- $\alpha$ mutations of hepatitis B virus affect genome replication and expression of surface antigens. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 843-850.	1.4	7
353	Analysis of miRNA expression patterns in human and mouse hepatocellular carcinoma cells. <i>Hepatology Research</i> , 2015, 45, 1331-1340.	1.8	7
354	Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C. <i>Journal of Korean Medical Science</i> , 2016, 31, 1431.	1.1	7
355	Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 241-247.	1.4	7
356	An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 177-186.	1.4	7
357	Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance. <i>Journal of Medical Virology</i> , 2018, 90, 497-502.	2.5	7
358	Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection. <i>PLoS ONE</i> , 2019, 14, e0214613.	1.1	7
359	A multi-centre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1352-1358.	1.0	7
360	Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. <i>Oncotarget</i> , 2017, 8, 79914-79926.	0.8	7

#	ARTICLE	IF	CITATIONS
361	Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 289-296.	1.0	7
362	Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea. <i>Yonsei Medical Journal</i> , 2006, 47, 793.	0.9	6
363	Hepatitis B Virus Serology to Predict Antiviral Response in Chronic Hepatitis B. <i>Digestion</i> , 2011, 84, 29-34.	1.2	6
364	Non-invasive assessment of liver fibrosis: The gap between ideal and real. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 937-939.	1.4	6
365	Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. <i>World Journal of Gastroenterology</i> , 2013, 19, 7671.	1.4	6
366	Prognostic Indicators for Acute Liver Failure Development and Mortality in Patients with Hepatitis A: Consecutive Case Analysis. <i>Yonsei Medical Journal</i> , 2014, 55, 953.	0.9	6
367	Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1049-1055.	1.4	6
368	Clinical predictors of silent but substantial liver fibrosis in primary Sjogren's syndrome. <i>Modern Rheumatology</i> , 2016, 26, 576-582.	0.9	6
369	Less Fibrotic Burden Differently Affects the Long-Term Outcomes of Hepatocellular Carcinoma after Curative Resection. <i>Oncology</i> , 2017, 93, 224-232.	0.9	6
370	Association between liver fibrosis and appendicular skeletal muscle mass during antiviral therapy in chronic hepatitis B. <i>Digestive and Liver Disease</i> , 2020, 52, 1338-1345.	0.4	6
371	Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2020, 27, 932-940.	1.0	6
372	High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1119-1126.	1.0	6
373	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2021, 62, 12.	0.9	6
374	External validation of CAGE and SAGE scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 951-958.	1.0	6
375	Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 403-412.	1.8	6
376	Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B. <i>Journal of Korean Medical Science</i> , 2020, 35, e104.	1.1	6
377	Use of sofosbuvir in chronic kidney disease: Is it necessary?. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 308-310.	4.5	6
378	Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large-scale Asian study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 156-170.	1.0	6

#	ARTICLE	IF	CITATIONS
379	Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. <i>Cancers</i> , 2021, 13, 5892.	1.7	6
380	Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients. <i>Cancers</i> , 2022, 14, 385.	1.7	6
381	Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study. <i>Hepatology Communications</i> , 2022, 6, 2455-2464.	2.0	6
382	A Case of Hypervascular Hyperplastic Nodules in a Patient with Alcoholic Liver Cirrhosis. <i>Yonsei Medical Journal</i> , 2006, 47, 881.	0.9	5
383	The Use of Health Functional Foods in Gastrointestinal Cancer Patients. <i>Clinical Nutrition Research</i> , 2013, 2, 19.	0.5	5
384	Non-O1, Non-O139 <i>Vibrio cholerae</i> Septicemia after Acupuncture. <i>The Ewha Medical Journal</i> , 2013, 36, S22.	0.1	5
385	Relationship between severity of liver dysfunction and the relative ratio of liver to aortic enhancement (RE) on MRI using hepatocyte-specific contrast. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 24-30.	1.9	5
386	Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. <i>Digestive and Liver Disease</i> , 2015, 47, 682-688.	0.4	5
387	Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. <i>Journal of Medical Virology</i> , 2017, 89, 85-90.	2.5	5
388	HBsAg-negative and anti-HBc-positive in eosinophilic granulomatosis with polyangiitis: a retrospective pilot study. <i>Rheumatology International</i> , 2018, 38, 1531-1538.	1.5	5
389	Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2021, 51, 406-416.	1.8	5
390	Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2479-2485.	1.4	5
391	Hepatitis B Core-Related Antigen: From Virology to Clinical Application. <i>Seminars in Liver Disease</i> , 2021, 41, 182-190.	1.8	5
392	Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 200-207.	1.4	5
393	Fatty liver associated with metabolic derangement in patients with chronic kidney disease: A controlled attenuation parameter study. <i>Kidney Research and Clinical Practice</i> , 2017, 36, 48-57.	0.9	5
394	Recombinant Interferon-Beta-1a Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot Study. <i>Gut and Liver</i> , 2009, 3, 20-25.	1.4	5
395	Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. <i>Gut and Liver</i> , 2017, 11, 693-701.	1.4	5
396	Multicenter Retrospective Risk Assessment of Esophageal Variceal Bleeding in Patients with Cirrhosis: An Acoustic Radiation Force Impulse Elastography-Based Prediction Model. <i>Gut and Liver</i> , 2019, 13, 206-214.	1.4	5

#	ARTICLE	IF	CITATIONS
397	Disease duration and Medsger's severity score are associated with significant liver fibrosis in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S68-74.	0.4	5
398	Tuberculous mesenteric lymphadenitis involving the gastric wall: case report. <i>Gastrointestinal Endoscopy</i> , 2005, 62, 799-802.	0.5	4
399	Clinical characteristics of acute hepatitis A complicated by acute kidney injury. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 144-148.	1.5	4
400	Predictors of Refractory Ascites Development in Patients with Hepatitis B Virus-Related Cirrhosis Hospitalized to Control Ascitic Decompensation. <i>Yonsei Medical Journal</i> , 2013, 54, 145.	0.9	4
401	Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1485-1493.	1.4	4
402	A novel risk score for hepatocellular carcinoma in Asian cirrhotic patients: a multicentre prospective cohort study. <i>Scientific Reports</i> , 2018, 8, 8608.	1.6	4
403	Psychometric evaluation of the Korean version of the Hepatitis B Quality of Life Questionnaire. <i>PLoS ONE</i> , 2019, 14, e0213001.	1.1	4
404	Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy. <i>Scientific Reports</i> , 2019, 9, 15628.	1.6	4
405	Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers. <i>Liver International</i> , 2019, 39, 81-89.	1.9	4
406	HKR3 regulates cell cycle through the inhibition of hTERT in hepatocellular carcinoma cell lines. <i>Journal of Cancer</i> , 2020, 11, 2442-2452.	1.2	4
407	Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1610-1618.	1.4	4
408	Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models. <i>Cell Death and Disease</i> , 2021, 12, 641.	2.7	4
409	Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1362-1372.	1.0	4
410	Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	4
411	Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 885-893.	0.8	4
412	Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 378-386.	1.4	4
413	Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 352-363.	4.5	4
414	Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization. <i>Cancers</i> , 2022, 14, 67.	1.7	4



#	ARTICLE	IF	CITATIONS
415	Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 196-204.	0.6	3
416	Cell culture-adaptive mutations of NS5A affect replication of hepatitis C virus differentially depending on the viral genotypes. <i>Journal of Medical Virology</i> , 2017, 89, 146-152.	2.5	3
417	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2427-2438.	1.1	3
418	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. <i>PLoS ONE</i> , 2020, 15, e0232186.	1.1	3
419	Pathological predictive factors for late recurrence of hepatocellular carcinoma in chronic liver disease. <i>Liver International</i> , 2021, 41, 1662-1674.	1.9	3
420	Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3123-3133.	1.2	3
421	Development and initial validation of the nonalcoholic fatty liver disease self-management questionnaire. <i>Research in Nursing and Health</i> , 2021, 44, 844-853.	0.8	3
422	Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients. <i>Journal of Korean Medical Science</i> , 2021, 36, e105.	1.1	3
423	Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 125-135.	4.5	3
424	Management of Clevidine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study. <i>Gut and Liver</i> , 2017, 11, 129-135.	1.4	3
425	Impact of Interferon-Based Treatment on Quality of Life and Work-Related Productivity of Korean Patients with Chronic Hepatitis C. <i>Gut and Liver</i> , 2020, 14, 368-376.	1.4	3
426	Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1346-1353.	0.7	3
427	Prediction of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis Using the P2/MS Noninvasive Index Based on Complete Blood Counts. <i>Digestion</i> , 2012, 86, 264-272.	1.2	2
428	Partial Virological Response to Adefovir Add-On Lamivudine Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B. <i>Digestion</i> , 2013, 87, 196-203.	1.2	2
429	Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy. <i>Liver International</i> , 2015, 35, 2370-2383.	1.9	2
430	A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 865-871.	1.4	2
431	Gene Expression Profiling of Hepatocellular Carcinoma Derived Cancer Stem Like Cell under Hypoxia. <i>Yonsei Medical Journal</i> , 2017, 58, 925.	0.9	2
432	Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1538-1544.	0.8	2

#	ARTICLE	IF	CITATIONS
433	Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 739-747.	0.8	2
434	Pharmacokinetics and safety of evogliptin in hepatically impaired patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 87, 2757-2766.	1.1	2
435	Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization. <i>Current Oncology</i> , 2021, 28, 965-977.	0.9	2
436	A Case of Lymphocyte-Rich Hepatocellular Carcinoma in a Patient Who Was Treated for Colon Cancer. <i>Journal of Liver Cancer</i> , 2021, 21, 69-75.	0.3	2
437	The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 467-476.	1.8	2
438	Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 399.	4.5	2
439	Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBVâ€DNA levelâ€%&lt;â€%2000ÂIU/mL. <i>Hepatology International</i> , 2022, 16, 294-305.	1.9	2
440	The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine. <i>Journal of Medical Virology</i> , 2016, 88, 820-827.	2.5	1
441	The remaining challenges of <sc>HCV</sc> treatment in the directâ€acting antivirals era. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1891-1892.	1.4	1
442	Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma. <i>Cancer Investigation</i> , 2021, 39, 274-283.	0.6	1
443	Predictors of Sarcopenia in an Obese Asian Population. <i>Nutrition and Cancer</i> , 2022, 74, 505-514.	0.9	1
444	Treatment of Chronic Hepatitis C Using Newly Developed Oral Antiviral Agents. <i>Korean Journal of Medicine</i> , 2015, 88, 635.	0.1	1
445	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. <i>Gut and Liver</i> , 2020, 14, 477-485.	1.4	1
446	Development and Pilot Testing of a Smartphone-Based Self-Care Program for Patients with Chronic Hepatitis B. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11139.	1.2	1
447	Hepatocellular Carcinoma with Bile Duct Tumor Thrombi. <i>Yeungnam University Journal of Medicine</i> , 2011, 28, 180.	0.1	1
448	External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study. <i>Cancers</i> , 2022, 14, 711.	1.7	1
449	Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis. <i>Diagnostics</i> , 2022, 12, 441.	1.3	1
450	Subclinical but significant liver fibrosis in patients with ANCA-associated vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 26-31.	0.4	1

#	ARTICLE	IF	CITATIONS
451	Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 576-584.	0.8	1
452	One Case of Tracheal Rupture after Blunt Chest Trauma Diagnosed Early by Fiberoptic Bronchoscopy. <i>Tuberculosis and Respiratory Diseases</i> , 1999, 46, 586.	0.2	0
453	Transient elastography in real practice: A time for action?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1134-1135.	1.4	0
454	Hepatic Sarcoidosis in a Patient with Chronic Hepatitis B Virus Infection. <i>Journal of Rheumatic Diseases</i> , 2015, 22, 200.	0.4	0
455	IDDF2019-ABS-0169...A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results. , 2019, , .		0
456	How do genetic variants affect our interpretation of noninvasive tests for nonalcoholic fatty liver disease?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 915-916.	1.4	0
457	IDDF2021-ABS-0080...96-week efficacy and safety of tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switch vs. continued TDF treatment among virologically-suppressed hepatitis B patients of asian ethnicity. , 2021, , .		0
458	IDDF2021-ABS-0078...Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD). , 2021, , .		0
459	A Delayed Hepatico-colonic Fistula after Radiofrequency Ablation in Hepatocellular Carcinoma. <i>Korean Journal of Medicine</i> , 2014, 86, 722.	0.1	0
460	Efficacy and safety of localized concurrent chemoradiation therapy and sorafenib sequential therapy in advanced hepatocellular carcinoma: A prospective phase II trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15678-e15678.	0.8	0
461	IDDF2020-ABS-0058...48-week safety and efficacy of switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) in chronic HBV asian patients with TDF risk factors (RF). , 2020, , .		0
462	IDDF2020-ABS-0060...Impact of prior tenofovir disoproxil fumarate (TDF) treatment duration on tenofovir alafenamide (TAF) safety profile in virally suppressed chronic HBV patients switched from TDF to TAF. , 2020, , .		0
463	Editorial: concurrent fatty liver and chronic viral hepatitis: a dual calamity leading to increased risk of hepatocellular carcinoma? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 481-482.	1.9	0
464	Dickkopf-1 promotes angiogenesis by upregulating VEGF receptor 2-mediated mTOR/p70S6K signaling in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2021, 11, 4788-4806.	1.4	0
465	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. , 2020, 15, e0232186.		0
466	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. , 2020, 15, e0232186.		0
467	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. , 2020, 15, e0232186.		0
468	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. , 2020, 15, e0232186.		0

#	ARTICLE	IF	CITATIONS
469	A micellized bone morphogenetic protein-7 prodrug ameliorates liver fibrosis by suppressing transforming growth factor- signaling.. American Journal of Cancer Research, 2022, 12, 763-778.	1.4	0